Signifying that it is no longer willing to compete in a crowded and contracting market, Johnson & Johnson’s Janssen Pharmaceuticals has decided to terminate its collaboration with Achillion Pharmaceuticals to develop and commercialise hepatitis C virus (HCV) products and regimens. The news follows Janssen’s announcement that it will discontinue further development of its JNJ-4178 HCV treatment regimen, which includes Achillion’s second-generation NS5A inhibitor odalasvir. Other deals to be terminated in September 2017 include Acrux’s licensing agreement with Eli Lilly for Axiron® (testosterone) and ThromboGenics licensing deal with Novartis’ Alcon for Jetrea® (ocriplasmin).